A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Liver Transplant Recipients

Trial Profile

A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Liver Transplant Recipients

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2009

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 30 Aug 2009 Results were presented at the 14th Congress of the European Society for Organ Transplantation.
    • 12 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top